Gentian Diagnostics AS (OSL:GENT) EBIT : kr2.9 Mil (TTM As of Sep. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Gentian Diagnostics AS EBIT?

Gentian Diagnostics AS's earnings before interest and taxes (EBIT) for the three months ended in Sep. 2024 was kr4.2 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Sep. 2024 was kr2.9 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Gentian Diagnostics AS's annualized ROC % for the quarter that ended in Sep. 2024 was 13.71%. Gentian Diagnostics AS's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was 30.79%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Gentian Diagnostics AS's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was 0.56%.

Gentian Diagnostics AS EBIT Historical Data

The historical data trend for Gentian Diagnostics AS's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gentian Diagnostics AS EBIT Chart

Gentian Diagnostics AS Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT

Get a 7-Day Free Trial

-27.15

-17.47

-23.41

-22.36

-9.57

Gentian Diagnostics AS Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
EBIT	Get a 7-Day Free Trial															0.02	-11.41	4.56	5.55	4.17

Competitive Comparison of Gentian Diagnostics AS's EBIT

For the Medical Devices subindustry, Gentian Diagnostics AS's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Gentian Diagnostics AS's EV-to-EBIT Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Gentian Diagnostics AS's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Gentian Diagnostics AS's EV-to-EBIT falls into.

Gentian Diagnostics AS EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr2.9 Mil.

Gentian Diagnostics AS (OSL:GENT) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Gentian Diagnostics AS's annualized ROC % for the quarter that ended in Sep. 2024 is calculated as:

	ROC % (Q: Sep. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Jun. 2024 )	+	Invested Capital (Q: Sep. 2024 ))	/ count )
=	10.868 * ( 1 - 0% )	/	( (84.201	+	74.345)	/ 2 )
=	10.868	/	79.273
=	13.71 %

where

	Invested Capital		(Q: Jun. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	186.863	-	21.647	-	( 81.015	-	max(0, 21.647	-	145.769	+	81.015	))
=	84.201

	Invested Capital		(Q: Sep. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	189.097	-	20.955	-	( 93.797	-	max(0, 20.955	-	147.542	+	93.797	))
=	74.345

Note: The Operating Income data used here is four times the quarterly (Sep. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Gentian Diagnostics AS's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Sep. 2024 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Jun. 2024		Q: Sep. 2024
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	16.684	/	( ( (17.039 + max(43.107, 0))	+	(15.426 + max(32.79, 0)) )	/	2 )
=	16.684	/	( ( 60.146	+	48.216 )	/	2 )
=	16.684	/	54.181
=	30.79 %

where Working Capital is:

	Working Capital		(Q: Jun. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(23.525	+	41.229	+	0)	-	(21.647	+	0	+	0)
=	43.107

	Working Capital		(Q: Sep. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(11.126	+	42.618	+	0.0010000000000048)	-	(20.955	+	0	+	0)
=	32.79

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Gentian Diagnostics AS's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Sep. 2024 )
	=	2.867	/	514.292
	=	0.56 %

Gentian Diagnostics AS EBIT Related Terms

Thank you for viewing the detailed overview of Gentian Diagnostics AS's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Gentian Diagnostics AS Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Gentian Diagnostics AS (OSL:GENT) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

Bjornasveien 5, Moss, NOR, 1596

Website

https://www.gentian.com

Gentian Diagnostics AS operates as a medical diagnostics company in Norway. It develops and produces in-vitro diagnostic reagents (IVD) for use in medical diagnostics and research. Its portfolio and pipeline of reagents span areas of inflammations, severe infections, kidney diseases, heart failures, and veterinary healthcare. The company's product portfolio includes the Gentian Cystatin C Immunoassay, the GCAL circulating calprotectin immunoassay (IVDR), the Gentian Retinol Binding Protein (RBP), and the Gentian Canine CRP among others. Geographically, it generates a majority of its revenue from Europe followed by Asia and the United States of America.